Statistics

Total Visits

Views
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)40

Select a period of time:

Number of views in the range

Views
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)26

Views

Views
November 20241
December 20240
January 20251
February 20257
March 202515
April 20252
May 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
Spain6
United States3
Canada1
Germany1
 

Top cities views

Views
Narón5
Council Bluffs1
Los Angeles1
Ottawa1